The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...

Novo Nordisk A/S (NVO) on Wednesday reported fourth-quarter earnings of $4.04 billion. The Bagsvaerd, Denmark-based company said it had net income of 91 cents per share. The results exceeded Wall ...

Novo Nordisk has a dominant position in diabetes and weight-loss drugs, strong financial growth outlook, and great potential. Click to read why NVO is a Strong Buy.

Novo Nordisk A/S Bagsværd, Denmark, 5 February 2025 – Novo Nordisk A/S has filed its Annual Report 2024 on Form 20-F for the financial year 2024 with the US Securities and Exchange Commission ...

President Donald Trump's threat of imposing a tariff on Denmark has the attention of one of the Triangle region's largest employers. STORY HIGHLIGHTS Novo Nordisk plans $4.1 billion expansion in ...

Novo Nordisk said on Wednesday it plan to file its experimental next-generation obesity drug CagriSema for regulatory approval during the first quarter of next year, slightly later than its previous ...

Bagsværd, Denmark, 4 February 2025 – On 11 November 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament ...

The two drugs have helped turn Novo Nordisk into Europe's biggest firm by market capitalisation and driven a considerable amount of Denmark's economic success. The Danish economy ministry cited ...

Danish drugmaker Novo Nordisk on Wednesday posted another quarter of rapid profit growth, though the story for once wasn’t its wildly popular weight-loss drugs. Novo Nordisk said its fourth ...